Pfizer announces FDA accepts supplemental new drug application for XELJANZ® (tofacitinib citrate) for the treatment of adult patients with moderately to severely active ulcerative colitis

14th July 2017 Uncategorised 0

Pfizer

More: Pfizer announces FDA accepts supplemental new drug application for XELJANZ® (tofacitinib citrate) for the treatment of adult patients with moderately to severely active ulcerative colitis
Source: MDlinx